Jacobs Levy Equity Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Jacobs Levy Equity Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,601	Closed	-$223K	–	1179
2020 Q4	$223K	Sell	2,601 -80,964	-97%	-$6.86M	﹤0.01%	956
2020 Q3	$5.43M	Buy	83,565 +27,230	+48%	+$1.78M	0.06%	322
2020 Q2	$4.12M	Sell	56,335 -2,366	-4%	-$126K	0.04%	378
2020 Q1	$2M	Buy	+58,701	New	+$2.68M	0.03%	473

Other funds holding BHVN

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jacobs Levy Equity Management's BHVN Position: Q1 2021 in Review

Jacobs Levy Equity Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2021, closing a stake of 2,601 shares — an estimated $223K sold.

Jacobs Levy Equity Management first reported a position in BHVN in Q1 2020 and held it in 4 quarters. The position peaked at $5.43M in Q3 2020. 224 funds tracked by Wall St. Rank hold BHVN as of Q1 2021.

Jacobs Levy Equity Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2021 after selling out during the quarter.
Jacobs Levy Equity Management sold 2,601 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2021, an estimated $223K.
Jacobs Levy Equity Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2020 and held it in 4 quarters.
Jacobs Levy Equity Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $5.43M in Q3 2020.
224 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2021, filed 17 May 2021.